Volume 28, Supplement—December 2022
SUPPLEMENT ISSUE
Surveillance
Incorporating COVID-19 into Acute Febrile Illness Surveillance Systems, Belize, Kenya, Ethiopia, Peru, and Liberia, 2020–2021
Table 1
Category | Belize | Kenya† | Ethiopia | Peru | Liberia |
---|---|---|---|---|---|
Surveillance start dates | |||||
AFI | 2020 Jan | 2006 Jan | 2021 Feb | 2021 Feb | 2018 Dec |
COVID-19 integration |
2020 Mar |
2020 May |
2021 Feb |
2021 Feb |
2021 Apr |
No. sites |
11 |
2 |
4‡ |
5 |
2 |
Inclusion criteria | |||||
Age | >60 d | All ages | >5 y | >10 y | >2 y (AFI), >5 y (COVID-19) |
Documented body temperature or history of fever | Axillary, oral, or rectal T >38°C or new fever <7 d before exam | Axillary T >38°C and <5 d of acute fever | Axillary, oral, or rectal T >38°C and fever for 2–14 d before exam | Axillary, oral, or rectal T >38°C and new fever <14 d before exam | Axillary, oral, or rectal T >37.5°C or fever <7 d before exam |
Afebrile patients |
>2 respiratory symptoms and high risk for or suspected SARS-CoV-2 infection or >2 GI symptoms |
None |
None |
None |
None |
Exclusion criteria | |||||
Surveillance protocol procedures | Previously enrolled within the past 7 d or declined follow up for disease outcomes | Previously enrolled | Previously enrolled | None | Previously enrolled within past year |
Chief complaint on arrival or during hospitalization |
Injury, trauma, or known cause of fever; returning with known cause of fever |
Injury or trauma |
Injury, trauma, focal infection, localizing symptoms, obstetric- or surgery-related cases |
Focal infection or fever onset >24 h after hospitalization (inpatients only) |
Injury, trauma, focal infection, returning with known cause of fever |
Data use methods§ | |||||
Collection | REDCap and paper-based form | Windows-based platform | Paper-based form | REDCap | Paper-based form |
Management |
REDCap |
Microsoft SQL servers |
Microsoft Excel |
Microsoft Access |
Epi Info |
Specimens |
Blood, NP/OP swabs, feces, eschar swabs |
Blood, NP/OP swabs;¶ urine |
Blood, NP/OP swabs¶ |
Blood, nasal MT swabs, saliva |
Blood, NP swabs¶ |
COVID-19 testing methods | Singleplex RT-PCR,# BioFire FilmArray respiratory panel** | RT-PCR# | Singleplex PCR# | CDC COVID-19 assay#†† | TaqPath COVID-19 CE-IVD RT-PCR#‡‡ |
*Data are sorted by COVID-19 integration month. AFI, acute febrile illness; GI, gastrointestinal; MT, mid-turbinate; NP, nasopharyngeal; OP, oropharyngeal; RT-PCR, reverse transcription PCR; T, temperature. †Data are from Kenya’s population-based infectious disease surveillance sites with survey-defined catchment areas. ‡Of 5 designated sites, only 4 were operational because of security issues. §REDCap (https://www.project-redcap.org); Microsoft Excel, Access, SQL Server, and Windows-based platform (https://www.microsoft.com); Epi Info (https://www.cdc.gov/epiinfo). ¶Additional specimens collected after COVID-19 surveillance integration into regular AFI surveillance activities. #Tests performed specifically for SARS-CoV-2. **BioFire (https://www.biofiredx.com). ††2019 nCoV Real-Time RT-PCR Diagnostic Panel, Centers for Disease Control and Prevention (https://www.cdc.gov/coronavirus/2019-ncov/lab/testing.html). ‡‡TaqPath COVID-19 CE-IVD RT-PCR kit, Thermo Fisher Scientific (https://www.thermofisher.com).
1These first authors contributed equally to this article.